Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
Michael Ayers
Study ID
NCT06023186
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • mavacamten — DRUG
    Study participants will receive mavacamten under the standard of care

Study Details

The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.

Key Dates

Start date
Nov 3, 2023
Status verified
Nov 2024
Primary completion
Aug 31, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: Cohort 1
    Clinically stable, adult patients with obstructive hypertrophic cardiomyopathy, who meet mavacamten prescribing guidelines will be prescribed mavacamten by their treating physician.

Primary Outcome Measure

Change in myocardial perfusion reserve after 12 months of mavacamten treatment. [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of VirginiaCharlottesvilleVirginia22908
Caroline L Flournoy
[email protected]
434-924-6104
Michael Ayers, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlottesville, VA

By research site
University of Virginia· Charlottesville, VA

Related Studies